Amlodipine Atenolol
Description
ROOTOPINE-A
Amlodipine and Atenolol Tablets
Division: DIABGLYM
Composition
Each tablet contains:
Amlodipine Besylate IP equivalent to Amlodipine — 5 mg
Atenolol IP — 50 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Oral tablet
Product Description
ROOTOPINE-A is a clinically effective antihypertensive combination of Amlodipine and Atenolol, formulated for the management of hypertension, chronic stable angina, and long-term cardiovascular risk reduction. This combination provides dual blood pressure control by combining the vasodilatory action of Amlodipine with the cardioselective beta-blocking effect of Atenolol, resulting in improved blood pressure control and enhanced cardiovascular protection.
Amlodipine is a long-acting dihydropyridine calcium channel blocker that relaxes vascular smooth muscle, reduces peripheral vascular resistance, and provides sustained 24-hour blood pressure control. Atenolol is a selective beta-1 adrenergic receptor blocker that reduces heart rate, myocardial contractility, and cardiac output, thereby lowering blood pressure and reducing myocardial oxygen demand.
ROOTOPINE-A is particularly beneficial in patients with hypertension associated with tachycardia, angina, coronary artery disease, diabetes, metabolic syndrome, and high cardiovascular risk. The combination helps achieve better blood pressure control while reducing cardiac workload and improving exercise tolerance in patients with ischemic heart disease.
Technical Knowledge of Amlodipine and Atenolol
Amlodipine inhibits L-type calcium channels in vascular smooth muscle, resulting in peripheral arterial vasodilation, reduced systemic vascular resistance, decreased afterload, and improved coronary blood flow. Its long elimination half-life provides effective once-daily blood pressure control.
Atenolol selectively blocks beta-1 adrenergic receptors in the heart, reducing sympathetic stimulation, heart rate, myocardial contractility, and renin secretion from the kidneys. This leads to a reduction in cardiac output and blood pressure while decreasing myocardial oxygen demand.
The combination of Amlodipine and Atenolol provides complementary antihypertensive mechanisms, improving blood pressure control while minimizing reflex tachycardia and providing additional anti-anginal benefits.
Mechanism of Action
Amlodipine relaxes vascular smooth muscle, reduces peripheral vascular resistance, lowers afterload, improves coronary blood flow, and provides sustained antihypertensive action.
Atenolol reduces heart rate, decreases myocardial contractility, lowers cardiac output, suppresses renin release, and reduces myocardial oxygen demand through selective beta-1 receptor blockade.
Key Benefits
Effective reduction of systolic and diastolic blood pressure
Dual antihypertensive mechanism
Sustained 24-hour blood pressure control
Reduces heart rate and myocardial workload
Improves coronary blood flow
Helps control chronic stable angina
Reduces cardiovascular risk
Enhances exercise tolerance
Suitable for once-daily long-term hypertension management under medical supervision
Clinical Applications
ROOTOPINE-A is commonly prescribed for essential hypertension, hypertension with tachycardia, chronic stable angina, coronary artery disease, hypertension with diabetes, hypertension with metabolic syndrome, ischemic heart disease, and long-term cardiovascular risk reduction.
Facts About Amlodipine and Atenolol
Amlodipine is one of the most widely prescribed calcium channel blockers due to its excellent efficacy, long duration of action, and favorable tolerability profile. Atenolol is a well-established cardioselective beta-blocker widely used in hypertension, angina, and ischemic heart disease. The combination is highly effective for patients requiring both heart rate control and sustained blood pressure reduction.
Key Facts
Dual antihypertensive combination therapy
Calcium channel blocker and beta-blocker combination
Provides sustained 24-hour blood pressure control
Effective in hypertension and chronic stable angina
Reduces cardiac workload and vascular resistance
Evidence-based cardiovascular combination therapy
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
ROOTOPINE-A is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, coronary artery disease, diabetes, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this combination.
Why Choose ROOTOPINE-A for PCD Pharma Franchise?
High prescription potential
Strong physician and cardiologist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Amlodipine and Atenolol Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented formulation
Moisture-controlled tablet manufacturing
Blister and Alu-Alu packaging options
ROOTOPINE-A from DIABGLYM combines effective blood pressure control, heart rate reduction, comprehensive cardiovascular protection, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable and evidence-based antihypertensive combination.
